Eli Lilly and Company (LLY)
Lilly CEO says tax and regulation reform, drug affordability are focuses under Trump
Eli Lilly CEO David Ricks on Tuesday said at the Economic Club of Washington that tax and regulation reform and drug affordability were some policy focuses for the company in a second Trump administration.
Lilly Will Test Obesity Drugs on Addiction, CEO Says
Eli Lilly & Co. will begin studies to see if its blockbuster weight-loss medicines can also be used to treat addictive behaviors like alcohol abuse, smoking and drug addiction, Chief Executive Officer Dave Ricks said. These medicines can be useful for other things we don't think about connected to weight,” Ricks said during an interview with David Rubenstein at a meeting of the Economics Club in Washington, DC.
Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts
Eli Lilly and Co LLY is making headlines with its $15 billion share buyback plan and a 15% dividend boost.
Jim Cramer reveals the most overlooked stock for 2025
Late on December 9, the former hedge fund manager and energetic host of Mad Money, Jim Cramer, took to X to share his two cents on which sectors in the stock market are overrepresented and which are being overlooked.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15%
LLY's board approves a new $15B stock buyback plan and announces a 15% increase in its quarterly dividend.
3 No-Brainer Growth Stocks to Buy in December
Growth. It's what most investors want more than anything else from their stocks. Some stocks can deliver more of it than others.
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Eli Lilly (LLY 0.13%) has produced a wide variety of treatments for various illnesses throughout its 145-year history. But this big pharma company truly took center stage over the past year or so, with the launches of two drugs that have been prescribed for a billion-dollar indication: weight loss.
How to Play LLY Stock as Zepbound Beats NVO's Wegovy in Obesity Study
The latest Zepbound data bodes well for Lilly and could help establish the drug as the new standard for obesity medications.
Eli Lilly Chief Scientific Officer explains Zepbound's weight loss advantage
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it means for Eli Lilly's future growth.
Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars
Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.
LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity Study
LLY's obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO's Wegovy in a head-to-head study.
